FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Codon topics
Hydrocodone
Nucleic Acid
Acetaminophen
Carboxylic Acid
Benzoic Acid
Genetically
Recombinant
Amino Acid
Nucleotide
Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitor
Reverse Transcriptase
Antibodies
Base Sequence
Replication

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Codon patents



      
           
This page is updated frequently with new Codon-related patent applications. Subscribe to the Codon RSS feed to automatically get the update: related Codon RSS feeds. RSS updates for this page: Codon RSS RSS


Date/App# patent app List of recent Codon-related patents
05/21/15
20150140639
 Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav patent thumbnailnew patent Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav
The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. Adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions.
Uniqure Ip B.v.
05/21/15
20150140574
 Method for producing horseradish peroxidase recombinant protein using filamentous fungus patent thumbnailnew patent Method for producing horseradish peroxidase recombinant protein using filamentous fungus
A modified polynucleotide has a different base sequence in at least one codon from a wild-type base sequence encoding a horseradish peroxidase polypeptide. The usage frequency of the modified codon of the polynucleotide corresponds to the codon usage frequencies of three filamentous fungal species in humicola, aspergillus, and trichoderma.
Meiji Seika Pharma Co., Ltd.
05/21/15
20150140139
 Composition for improving or promoting hair growth containing, as active ingredients, photosensitizer irradiated with light and peptide, and method using same patent thumbnailnew patent Composition for improving or promoting hair growth containing, as active ingredients, photosensitizer irradiated with light and peptide, and method using same
The present invention relates to a composition for improving or promoting hair growth, which contains, as an active ingredient, a photosensitizer-peptide conjugate, and to a method for screening for the hair growth promoter using the active ingredients. Ala, which is the photosensitizer of the present invention, is preferably activated by led radiation, and more preferably activated by radiation having a long wavelength of 650 to 675 nm.
Gwangju Institute Of Science And Technology
05/21/15
20150140103
 Vaccine patent thumbnailnew patent Vaccine
The present invention relates to a nucleic acid for vaccine that has undergone codon optimization for expression in bombyx mori, a vector comprising the nucleic acid, bombyx mori comprising the vector, and a method for producing a vaccine in which they are used.. .
The Institute Of Biological Resources
05/21/15
20150140095
 Once-a-day oxycodone formulations patent thumbnailnew patent Once-a-day oxycodone formulations
The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean c24/cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.. .
Purdue Pharma L.p.
05/14/15
20150133665
 Processes and intermediates in the preparation of morphine analogs via n-demethylation of n-oxides using cyclodehydration reagents patent thumbnailProcesses and intermediates in the preparation of morphine analogs via n-demethylation of n-oxides using cyclodehydration reagents
A high-yielding method for the n-demethylation of oxycodone- and oxymorphone-n-oxides by the reaction of these compounds with cyclodehydration reagents has been performed. This method has been utilized to improve the synthesis of various morphine analogs, such as naltrexone, nalbuphone and naloxone..
05/14/15
20150132752
 Method for determining hla-a*24 group patent thumbnailMethod for determining hla-a*24 group
The method of the present invention is a method for determining an hla-a*24 group, which includes determining the hla-a*24 group on the basis of the results of the typing of (a) a 211st base and (b) a 395th base, in which a (adenine) in the initiation codon for an hla gene is defined as the 1st base in the genomic dna of a test subject.. .
04/30/15
20150119556
 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same patent thumbnailHistidine engineered light chain antibodies and genetically modified non-human animals for generating the same
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
Regeneron Pharmaceuticals, Inc.
04/30/15
20150119293
 Synthetic ligation reassembly in directed evolution patent thumbnailSynthetic ligation reassembly in directed evolution
A directed evolution process for rapid and facilitated production from a progenitor polynucleotide template, of a library of mutagenized progeny polynucleotides wherein each of the 20 naturally encoded amino acids is encoded at each original codon position. This method, termed site-saturation mutagenesis, or simply saturation mutagenesis, is preferably based on the use of the degenerate n,n,g/t sequence.
Bp Corporation North America Inc.
04/23/15
20150110870
 Controlled release hydrocodone formulations patent thumbnailControlled release hydrocodone formulations
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.
04/16/15
20150105537

Codon optimized sequence for an antiviral protein


A codon optimized nucleic acid sequence for interferon alpha-2a is provided which can be used for expression of interferon alpha-2a in e. Coli..
Biogenomics Limited
04/09/15
20150099798

Variants of yeast ndi1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction


An isolated nucleic acid sequence encoding the yeast ndi1 protein of seq id no: 542 or a functional variant thereof is described. The nucleic acid sequence comprises at least 50 codons which are codon optimised compared with the sequence of yeast ndi1 gene of seq id no: 1..
Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin
04/09/15
20150099281

Method for producing l-lysine using microorganisms having ability to produce l-lysine


The present invention relates to a modified polynucleotide encoding aspartate kinase (ec:2.7.2.4; hereinafter, referred to as lysc), transketolase (ec:2.2.1.1; hereinafter, referred to as tkt) or pyruvate carboxylase (ec:6.4.1.1; hereinafter, referred to as pyc), in which the initiation codon is substituted with atg, a vector including the same, a microorganism transformed with the vector, and a method for producing l-lysine using the same.. .
Cj Cheiljedang Corporation
04/02/15
20150094231

Oligonucleotides and methods for detecting kras and pik3ca mutations


Provided are oligonucleotides that are capable of detecting kras and pik3ca mutations in both cancer patients and healthy individuals with high specificity in kpcr assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of kras codon 12, 13, and 61 and pik3ca codon 542, 545, and 1047 single nucleotide polymorphisms (snps) in a background of wild-type sequences.
Siemens Healthcare Diagnostics Inc.
03/26/15
20150087667

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof


The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
Kempharm, Inc.
03/26/15
20150087666

Oral dosage forms for oxygen containing active agents and oxyl-containing polymers


The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, a tri-oxy active agent, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts.
03/26/15
20150086658

Herbal composition for treating metastatic breast cancer


The invention provides a composition comprising a mixture of extracts obtained from atractylodes macrocephala, astragalus membranaceus, taraxacum mongolicum, poria cocos, ligusticum chuanxiong, ligustrum lucidum, codonopsis pilosula, glycyrrhiza uralensis, hedyotis diffusa, pseudostellaria heterophylla, and viola philippica. The present invention further provides a method for treating metastatic breast cancer in a subject in need thereof, comprising: administering to said subject an pharmaceutically effective amount of the composition..
03/19/15
20150082496

Rice gene, gs3, exerting primary control over grain length and grain weight


The present invention relates to an isolated major gene gs3 which regulates grain weight and grain length in the rice and the cloning of said gene. The dna sequence of gs3 gene is as shown in seq id no.
Huazhong Agricultural University
03/19/15
20150080423

Pharmaceutical combinations of hydrocodone and naltrexone


Disclosed is a pharmaceutical composition comprising from about 5 to about 20 mg of hydrocodone or a pharmaceutically acceptable salt thereof and from 0.055 to about 0.56 mg naltrexone or pharmaceutically acceptable salt thereof.. .
Purdue Pharma L.p.
03/19/15
20150079630

Cyclic rna and protein production method


The present invention provides a cyclic rna preferable for carrying out rotary protein translation in which translation domains other than that of the target protein are sufficiently short and translation efficiency is high, and a method for producing protein that uses this cyclic rna as template. More specifically, the present invention provides a cyclic rna that encodes a protein, has a full-length number of bases that is equal to or greater than 102 and is a multiple of 3, has at least one start codon, does not have a stop codon in the same reading frame as the start codon, and does not contain an internal ribosome entry site (ires).
Riken
03/19/15
20150079128

Chinese medicinal formulation for treating inflammatory bowel disease and the preparation thereof


This invention relates to a chinese medicinal formulation for the treatment of inflammatory bowel diseases, and a method of preparation thereof. The formulation comprises herbal components selected from a group consisting of radix codonopsis (dangshen), rhizoma atractylodis macrocephalae (bai zhu), sclerotium poriae cocos (fu ling), rhizoma zingiberis officinalis (gan jiang), radix paeoniae alba (bai shao) and rhizoma coptidis (huanglian)..
Hong Kong Baptist University
03/12/15
20150071995

Abuse resistant forms of extended release hydrocodone, use and making


An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (gi) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided..
Inspirion Delivery Technologies, Llc
03/05/15
20150065536

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof


The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
Kempharm, Inc.
03/05/15
20150064247

Abuse resistant forms of immediate release hydrocodone, use and making


An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (gi) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided..
Inspirion Delivery Technologies, Llc
02/26/15
20150056654

Process for the purification of recombinant albumin


A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilised aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography.
Novozymes Biopharma Dk A/s
02/26/15
20150056230

Equine encephalitis virus vaccines and methods of using thereof


Disclosed herein are nucleotide sequences which encode a plurality of structural proteins, except the capsid, of an equine encephalitis virus, wherein the nucleotide sequence is codon-optimized for mammalian expression. The nucleotide sequences are codon-optimized for expression in humans.
02/19/15
20150051251

Premature-termination-codons readthrough compounds


Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.. .
The Regents Of The University Of California
02/19/15
20150050339

Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, making and use thereof


The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
Kempharm, Inc.
02/12/15
20150045383

Treating pain in patients with hepatic impairment


An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Zogenix, Inc.
02/12/15
20150044282

Abuse resistant forms of immediate release oxycodone, use and making


An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (gi) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided..
Inspirion Delivery Technologies, Llc
02/12/15
20150044247

Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses


Described herein is the generation of optimized h3n2, h2n2 and b influenza ha polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on h3n2, h2n2 and b influenza isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
02/05/15
20150037409

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.
01/22/15
20150026834

Anastasis biosensor


The present invention relates to the field of anastasis, i.e., the process of reversal of apoptosis. More specifically, the present invention provides methods and compositions useful for studying anastasis.
The Johns Kopkins University
01/22/15
20150025044

Identification and use of compounds that affect the fidelity of eukaryotic translation initiation codon selection


A screening method for identifying compounds that alter the fidelity with which the initiation codon in mrnas is recognized by the translational apparatus in eukaryotes is disclosed. This screening method was used to identify compounds having such activity.
The Johns Hopkins University
01/22/15
20150024438

Heterologous expression of termite cellulases in yeast


The present invention provides for heterologous expression of termite and termite-associated symbiont cellulases. The cellulases can, for example, be codon-optimized and expressed in yeast host cells, such as the yeast saccharomyces cerevisiae.
Mascoma Corporation
01/15/15
20150017196

Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses


Described herein is the generation of optimized h5n1 and h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on h5n1 and h1n1 influenza isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
01/08/15
20150010945

Methods and systems for tracking bioremediation processes


A method for expression of engineered constructs containing sequences coding for functional genes of interest in e. Coli strains.
Arizona State Board Of Regents For And On Behalf Of Arizona State University
01/01/15
20150005249

Readthrough inducing agent and drug for treating genetic disease caused by nonsense mutation


A readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations, the readthrough inducing agent comprising a compound having a structure expressed by the following structural formula (a), and a drug for treating a genetic disease caused by nonsense mutations, the drug comprising the readthrough inducing agent.. .
University Of Tokyo
12/25/14
20140378498

Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia


The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof..
Mallinckrodt Llc
12/25/14
20140378496

Opioid analgesics and 3-hydroxyacetanilide for treating pain


Pharmaceutical combinations of opioid analgesics and analgesics that act through non-opioid mechanisms are commonly used to provide pain relief. An example of this pharmaceutical combination is the product vicodin™, where the opioid analgesic is hydrocodone and the non-opioid is acetaminophen.
Slx Pharmaceuticals, Llc
12/25/14
20140377800

Method for achieving improved polypeptide expression


The present invention relates to methods of optimization of a protein coding sequences for expression in a given host cell. The methods apply genetic algorithms to optimise single codon fitness and/or codon pair fitness sequences coding for a predetermined amino acid sequence.
Dsm Ip Assets B.v.
12/25/14
20140377349

Controlled release oral dosage form comprising oxycodone


The present invention relates to a controlled-release oral dosage form for administration of oxycodone once a day and a method of preparing a controlled-release oral dosage form for administration of oxycodone once a day.. .
Develco Pharma Schweiz Ag
12/25/14
20140377348

Controlled release hydrocodone formulations


A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a c12/cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours..
Purdue Pharma L.p.


Popular terms: [SEARCH]

Codon topics: Hydrocodone, Nucleic Acid, Acetaminophen, Carboxylic Acid, Benzoic Acid, Genetically, Recombinant, Amino Acid, Nucleotide, Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitor, Reverse Transcriptase, Antibodies, Base Sequence, Replication

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













0.5319

3287

459291 - 0 - 76